Board of Directors
Aloyzas Petrikas, Board Member
Al Petrikas is a successful entrepreneur. An American citizen, he founded and lead several companies, including Vitta Corporation. He has more than 30 years of management experience in product development. He has served on the Board of Directors of the Connecticut Business and Industry Association and also the Fairfield County Business Development Board.
Jason Rushton, Partner Xeraya Capital, Board Member
Mr. Rushton is a partner in Xeraya Capital, a global venture capital firm that invests in the life sciences sector. From 2011 to 2016, Mr. Rushton was a director in the corporate finance advisory arm of Deloitte & Touche LLP. Prior to that, Mr. Rushton was an independent strategy consultant, and an investment manager at Inventages Venture Capital Investment, Inc., an investment arm of Nestle S.A. specializing in the health care and life sciences sectors. Mr. Rushton was an associate in Merlin Biosciences Fund, L.P., a venture capital firm specializing in life science companies, and a management consultant in PA Consulting Group, a global management consulting firm. Mr. Rushton started his career at Eli Lilly and Company as a biologist. Mr. Rushton holds a Bachelor of Science in Anatomy and a Master of Science in Immunology from the University of Birmingham.
Christopher Hunt, CEO Imprimatur Capital Limited, Board Member
Christopher joined Imprimatur Capital in 2013 as the COO and took over as CEO in 2017. Imprimatur Capital is an international boutique science and technology investment company, specializing in long term intellectual property (IP) opportunities. He founded Fair-Lead Partners which was a FCA regulated boutique advisory firm, in 2009 after a seventeen year career with blue chip Investment banks, predominantly in Asia. As a Managing Director and Head of Asian Equities, at Cazenove Asia, Christopher was responsible for the regulatory operation of the platform, with ninety research, sales and trading staff in five global locations. He had operational oversight of the business and was an integral part of the sale of Cazenove Asia to Standard Chartered Bank. Previously, he was an Executive Director of Equity Capital Markets (ECM) and Global Head of Asian Equity Syndicate at Morgan Stanley Asia. He has extensive experience in ECM transactions, Initial Public Offerings and allocations and operational risk.
(Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd, Board Member
Teo Forcht Dagi is an experienced leader with a distinguished career in neurosurgery, medical innovation and venture capital. Dr. Dagi is a board certified neurosurgeon trained at the Massachusetts General Hospital. He holds faculty appointments at Harvard Medical School and Queen’s University Belfast. He served as President of the Georgia Neurosurgical Society and as a Director of the American Association of Neurological Surgeons. He has sat on numerous public and private boards, has been involved in many start-ups and early stage companies, and served as a partner at and advisor to prominent venture capital funds. He received an AB from Columbia, and an MD and MPH from Johns Hopkins. He holds an MBA with distinction from Wharton and was awarded a DMedSc (Honoris Causae) from Queen’s University Belfast for contributions to medicine and public service.